Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0042-1756477
The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective
Funding Funding for this study was provided by Viatris (Mylan India)![](https://www.thieme-connect.de/media/10.1055-s-00050348/202404/lookinside/thumbnails/10-1055-s-0042-1756477_22430679-1.jpg)
Abstract
Management of chronic myeloid leukemia (CML) has been transformed by the use of tyrosine kinase inhibitors (TKIs). Presently in India, five TKIs are approved for the management of CML with distinct safety profiles. The selection of TKIs for chronic phase (CP)-CML patients is based on treatment goals, underlying comorbidities, and specific TKI toxicity profiles. Bosutinib is one of five TKIs indicated for the first-line treatment of CP-CML and patients with intolerance or resistance to prior TKI therapy. It possesses a distinct safety profile among other TKIs, with less cardiovascular adverse events (AEs), albeit the liver-related and gastrointestinal AEs have higher occurrence. The safety and efficacy of bosutinib have been examined in clinical trials; however, there is a paucity of data from Asia. A virtual expert panel meeting was convened to gather expert opinion from India on the selection of bosutinib as a treatment choice for patients with CP-CML. This is a white paper document drafted with the help of an expert panel of 14 oncologists and hematooncologists from India on bosutinib use in CP-CML. The experts concurred that bosutinib has proven efficacy for CP-CML in global randomized clinical trials and is well suited for CP-CML patients with existing cardiovascular comorbidities. However, it was not recommended for patients with gastrointestinal, pancreatic, or renal abnormalities. This review aims to put forth expert opinion and guidance document on key considerations for CP-CML clinical decision-making in India.
Authors' Contributions
All authors adhered to the ICMJE authorship criteria. All authors reviewed and revised the manuscript for important intellectual content.
Publication History
Article published online:
28 November 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Arber DA, Orazi A, Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20) 2391-2405
- 2 Radich JP, Deininger M, Abboud CN. et al. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018; 16 (09) 1108-1135
- 3 Hochhaus A, Saussele S, Rosti G. et al; ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl. 04) iv41-iv51
- 4 Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340 (17) 1330-1340
- 5 ACS. American Cancer Society; Chronic myeloid leukemia. Accessed August 26, 2020 at: https://www.cancer.org/cancer/chronic-myeloid-leukemia.html
- 6 Au WY, Caguioa PB, Chuah C. et al. Chronic myeloid leukemia in Asia. Int J Hematol 2009; 89 (01) 14-23
- 7 Dikshit RP, Nagrani R, Yeole B, Koyande S, Banawali S. Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years. Indian J Med Paediatr Oncol 2011; 32 (02) 96-100
- 8 WHO. . World Health Organization; International Agency for Research on cancer; India Source: Globocan 2018. 2018. Accessed October 01, 2020, at: https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf
- 9 Kennedy JA, Hobbs G. Tyrosine kinase inhibitors in the treatment of chronic-phase CML: strategies for frontline decision-making. Curr Hematol Malig Rep 2018; 13 (03) 202-211
- 10 Ganesan P, Kumar L. Chronic myeloid leukemia in India. J Glob Oncol 2016; 3 (01) 64-71
- 11 Yanamandra U, Malhotra P. CML in India: are we there yet?. Indian J Hematol Blood Transfus 2019; 35 (01) 1-2
- 12 Labs P. BOSULIF® (bosutinib) tablets, Prescribing Information. 2017. Accessed August 10, 2022, at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203341s009lbl.pdf
- 13 USFDA. ARIAD Pharmaceuticals, Inc. ICLUSIG® (ponatinib) tablets for oral use 2012. Accessed October 01, 2020, at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf
- 14 Hughes TP, Kaeda J, Branford S. et al; International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349 (15) 1423-1432
- 15 Redaelli S, Piazza R, Rostagno R. et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009; 27 (03) 469-471
- 16 Steinbach A, Clark SM, Clemmons AB. Bosutinib: a novel src/abl kinase inhibitor for chronic myelogenous leukemia. J Adv Pract Oncol 2013; 4 (06) 451-455
- 17 Hochhaus A, Saglio G, Hughes TP. et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30 (05) 1044-1054
- 18 Cortes JE, Saglio G, Kantarjian HM. et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol 2016; 34 (20) 2333-2340
- 19 Cortes JE, Gambacorti-Passerini C, Deininger MW. et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol 2018; 36 (03) 231-237
- 20 Cortes JE, Kim D-W, Kantarjian HM. et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30 (28) 3486-3492
- 21 Smith G, Apperley J, Milojkovic D. et al; British Society for Haematology. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol 2020; 191 (02) 171-193
- 22 Chen K-K, Du T-F, Wu K-S, Yang W. First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Manag Res 2018; 10: 3891-3910
- 23 Fachi MM, Tonin FS, Leonart LP. et al. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: a systematic review and network meta-analysis. Eur J Cancer 2018; 104: 9-20
- 24 Fachi MM, Tonin FS, Leonart LP, Rotta I, Fernandez-Llimos F, Pontarolo R. Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: a network meta-analysis. Br J Clin Pharmacol 2019; 85 (10) 2280-2291
- 25 Hughes T, Saglio G, Branford S. et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009; 27 (25) 4204-4210
- 26 Müller MC, Cortes JE, Kim D-W. et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009; 114 (24) 4944-4953
- 27 Cortes JE, Kantarjian HM, Brümmendorf TH. et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011; 118 (17) 4567-4576
- 28 O'Hare T, Shakespeare WC, Zhu X. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16 (05) 401-412
- 29 Apperley JF, Byrne JL, Smith G. et al. The real world use of bosutinib in patients with chronic myeloid leukaemia. Blood 2016; 128 (22) 5435-5435
- 30 Garcia-Gutierrez JV, Maestro BA, Casado LF. et al. Switching to a second generation TKI in chronic myeloid leukemia patients with late suboptimal response with imatinib obtained better molecular responses that the “watch and wait” approach. an experience of a multicenter registry in patients outside clinical trials. Blood 2012; 120 (21) 3768-3768
- 31 Suh KJ, Lee JY, Shin DY. et al. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. Int J Hematol 2017; 106 (02) 229-239
- 32 Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogné JM. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf 2017; 16 (01) 5-12
- 33 Novo G, Di Lisi D, Bronte E. et al. Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors: a real-world single-center experience. Oncology 2020; 98 (07) 445-451
- 34 Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol 2016; 2 (05) 625-632
- 35 Gambacorti-Passerini C, Brümmendorf TH, Kim D-W. et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up. Am J Hematol 2014; 89 (07) 732-742
- 36 Brümmendorf TH, Cortes JE, Khoury HJ. et al. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Br J Haematol 2016; 172 (01) 97-110
- 37 Cortes JE, Muresan B, Mamolo C. et al. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Curr Med Res Opin 2019; 35 (09) 1615-1622
- 38 Gambacorti-Passerini C, Kantarjian HM, Kim DW. et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol 2015; 90 (09) 755-768
- 39 Ault PS, Rose PharmD J, Nodzon PhD LA, Kaled ES. Bosutinib therapy in patients with chronic myeloid leukemia: practical considerations for management of side effects. J Adv Pract Oncol 2016; 7 (02) 160-175
- 40 Kantarjian HM, Cortes JE, Kim DW. et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 2014; 123 (09) 1309-1318
- 41 Khoury HJ, Gambacorti-Passerini C, Brümmendorf TH. Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Ann Oncol 2018; 29 (03) 578-587
- 42 Cortes JE, Apperley JF, DeAngelo DJ. et al. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol 2018; 11 (01) 143-143
- 43 Ono T, Takahashi N, Kizaki M. et al. Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor. Cancer Sci 2020; 111 (10) 3714-3725
- 44 Saussele S, Krauss M-P, Hehlmann R. et al; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 2015; 126 (01) 42-49
- 45 Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 2015; 94 (2, Suppl 2): S241-S247
- 46 Latagliata R, Attolico I, Trawinska MM. et al. Bosutinib in the real-life treatment of chronic phase chronic myeloid leukemia (CML) patients aged >65 years resistant/intolerant to frontline tyrosine-kynase inhibitors. Blood 2019; 134 (Supplement_1): 1649-1649
- 47 Castagnetti F, Gugliotta G, Bocchia M. et al. Dose optimization in elderly CML patients treated with bosutinib after intolerance or failure of first-line tyrosine kinase inhibitors. Blood 2019; 134 (Supplement_1): 496-496
- 48 Flynn KE, Weinfurt KP, Lin L. et al. Patient-reported outcome results from the U.S. life after stopping TKIs (LAST) study in patients with chronic myeloid leukemia. Blood 2019; 134 (Supplement_1): 705-705
- 49 Alfayez M, Kantarjian HM, Kadia TM. et al. Ponatinib and bosutinib discontinuation in chronic myeloid leukemia (CML): single center experience. Blood 2018; 132 (Supplement 1): 5447-5447
- 50 Hochhaus A, Larson RA, Guilhot F. et al; IRIS Investigators. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017; 376 (10) 917-927
- 51 Shah NP, Rousselot P, Schiffer C. et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180–034. 2016; 91 (09) 869-874
- 52 Giles FJ, le Coutre PD, Pinilla-Ibarz J. et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013; 27 (01) 107-112
- 53 Cortes JE, Khoury HJ, Kantarjian HM. et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol 2016; 91 (12) 1206-1214